Paracetamol N-Methyl-D-glucamine Raw Materials Powder

CAS:6284-40-8

MF: C7H17NO5

MW: 195.21

EINECS:228-506-9

Specification​: 99% min N-Methyl-D-glucamine Powder

Sample: N-Methyl-D-glucamine Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

N-Methyl-D-glucamine Powder Usage and Synthesis.

Clinically used for the treatment of:

1. Heart failure: it has good effect on heart failure caused by various reasons such as hypertensive heart disease, coronary atherosclerotic heart disease (coronary heart disease) and cardiomyopathy.

2. Coronary atherosclerotic heart disease (coronary heart disease): this product reduces myocardial oxygen consumption, improves myocardial cell metabolism, protects ischemic and hypoxic myocardium; at the same time, it expands coronary arteries, improves coronary artery circulation, and increases the myocardial supply of oxygen, so it is suitable for the treatment of acute myocardial infarction, and the treatment of stable exertional angina pectoris has a definite efficacy.

3. Acute myocarditis: heart failure, ventricular tachycardia and atrioventricular block caused by myocarditis can be improved or restored to varying degrees, and the enlarged heart can be shrunk.

4. Dilated cardiomyopathy: cardiac function and electrocardiogram have been improved after using the drug, and the enlarged heart of some patients has been significantly reduced or returned to normal.

5. Sick sinus node syndrome: it is suitable for patients in early or evolving stage, and there are different degrees of recovery for sinus quiescence, sinus block and slow-fast syndrome.

6. Ventricular pre-systole: It is effective in ventricular pre-systole and other arrhythmias caused by various reasons, and can be used as an adjunctive drug in the treatment of arrhythmia.

Uses and functions of N-Methyl-D-glucamine.

Meglumine may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Pharmacological Effects of N-Methyl-D-glucamine Raw Materials.

N-Methyl-D-glucamine can maximise the pharmacological effect of cAMP by enhancing the lipid solubility of cAMP and improving the purity of cAMP.

cAMP has positive inotropic effect, relaxation of smooth muscle, regulating the second messenger function, and its pharmacological effects are shown as follows:

1. Positive inotropic effect: MCA is a non-digital cardiac drug, which can increase myocardial contractility and improve the pumping function of the heart.

2. Vasodilator effect: dilate peripheral blood vessels, reduce the anterior and posterior load on the heart.

3. Improve myocardial metabolism: reduce coronary resistance, increase myocardial oxygen supply, improve oxygen utilisation. 4. Inhibit platelet activity: inhibit thrombin-induced elevation of free calcium in human platelets, thereby inhibiting platelet activation, indirectly playing a protective role in the cardiovascular. 5.

5. Anti-arrhythmic effect: delay the latency period of adrenaline-induced arrhythmia, shorten the duration of arrhythmia, and reduce the incidence of calcium-induced ventricular fibrillation and ventricular tachycardia. Regulation of P-cell function: MCA plays the role of second messenger to regulate P-cell function, and at the same time has the effect of promoting cell growth.

Production method of N-Methyl-D-glucamine Raw Powder.

It is obtained by condensation of glucose with monomethylamine followed by catalytic hydrogenation.

Anhydrous ethanol and dry glucose were added to the reaction pot, and dry monomethylamine gas was passed at 50°C. After 1.5-2h of reaction, the solution was gradually clarified, and continued to be kept at 50°C for 2h to obtain glucose condensed methylamine solution. Then add it into the autoclave, in the presence of Lei's nickel, through the hydrogen pressure to 2.5MPa, stirring at 80-85 ℃ for 1-2h. Then after cooling pressure relief discharge, the upper layer of glucose methylamine ethanol solution cooling crystallisation, filtration, the glucose methylamine crude product, and then refined and finished products.